Serina Therapeutics (SER) AI Stock Analysis

• Market Cap: $28.47M
• Dividend Yield: N/A
• Average Volume (3M): 24.47K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.18
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 12
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.45
• Shares Outstanding: 10,664,064
• 10 Day Avg. Volume: 14,098
• 30 Day Avg. Volume: 24,472
• PEG Ratio: <0.01
• Price to Book (P/B): 57.52
• Price to Sales (P/S): 658.37
• P/FCF Ratio: -2.15
• Enterprise Value/Market Cap: 1.92
• Enterprise Value/Revenue: 472.16
• Enterprise Value/Gross Profit: 829.85
• Enterprise Value/Ebitda: -2.96
• 1Y Price Target: $11.00
• Price Target Upside: 308.92% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 42 Neutral
• Price Target: $2.50 ▼(-7.06% Downside)

The score is driven primarily by weak financial performance (large losses and cash burn with limited equity cushion), reinforced by bearish technicals (below key moving averages and negative MACD). A negative P/E and the NYSE compliance deficiency notice further weigh on the outlook.

Positive Factors

Proprietary drug-delivery platform

Serina’s focus on proprietary drug delivery systems and novel therapeutics provides durable product and licensing opportunities. Platform assets support recurring revenue streams via product sales, partnerships, and royalties, underpinning long-term commercialization and collaboration potential.

Manageable reported leverage

Recent low debt relative to assets offers financial flexibility versus highly leveraged peers. Manageable leverage reduces near-term solvency pressure and interest burden, enabling the company to prioritize R&D and partnership negotiations without immediate debt servicing constraints.

Lean operating footprint

A very small headcount suggests a lean cost structure and operational efficiency, extending runway per dollar raised and allowing focused investment in core programs. This nimble model supports capital efficiency and quick strategic pivots as development milestones evolve.

Negative Factors

Substantial cash burn

Deeply negative operating and free cash flows indicate the business cannot self-fund development, requiring recurring external financing. Persistent cash burn strains runway, increases dilution risk, and constrains the company’s ability to advance multiple programs or invest in commercialization infrastructure.

Sustained operating losses

Ongoing large operating losses and declining revenues undermine prospects for near-term profitability. Reliance on non-recurring items for prior positive results shows earnings instability, making long-term margin sustainability and predictable free cash generation uncertain without material commercial or pipeline breakthroughs.

Funding and dilution risk

Negative historical equity combined with approved issuance tied to convertible notes and warrants signals dependence on dilutive financing. This structural funding reliance can erode shareholder value, limit strategic flexibility, and force future dilutive raises if cash burn persists or partnerships are delayed.

Serina Therapeutics Business Overview & Revenue Model

Company Description

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.

How the Company Makes Money

Serina Therapeutics generates revenue primarily through the commercialization of its proprietary drug delivery technologies and therapeutic products. The company may also engage in strategic partnerships and collaborations with larger pharmaceutical firms, which can provide upfront payments, milestone payments, and royalties on future sales. Additionally, research grants and funding from government agencies or private investors focused on innovative medical treatments contribute to its financial resources. The success of clinical trials and the approval of its products can significantly impact its revenue streams, as successful therapies move into the market.

Serina Therapeutics Financial Statement Overview

Summary

Serina Therapeutics is facing severe financial challenges across all key financial statements. The income statement reflects substantial losses and declining revenue, the balance sheet is under strain due to high liabilities and negative equity, and cash flow issues point to operational inefficiencies. These factors collectively suggest a need for strategic restructuring or significant operational improvements to ensure future viability.

Income Statement

Serina Therapeutics has experienced significant volatility in revenue and profitability. The TTM data shows a drastic decline in revenue, leading to negative gross and net profit margins. This indicates severe inefficiencies and a struggle to generate sufficient income. Previous periods also reflect a trend of high losses, with EBIT and EBITDA margins persistently underperforming.

Balance Sheet

The balance sheet shows a concerning financial structure with a very low equity base and high liabilities, resulting in a negative equity in some periods. The debt-to-equity ratio is not ideal, and the return on equity is not calculable due to negative equity. This suggests high financial risk and instability.

Cash Flow

The cash flow statement highlights consistent negative free cash flow, indicating operational challenges. The operating cash flow is significantly negative, suggesting that the company struggles to generate cash from its core activities. Despite some positive financing activities, the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	116.00K	56.00K	3.15M	500.00K	3.04M	54.00K
Gross Profit	66.00K	-138.00K	3.06M	500.00K	3.04M	-1.23M
EBITDA	-18.49M	-10.49M	5.92M	-2.60M	-1.23M	-8.74M
Net Income	-18.59M	-11.14M	5.27M	-2.68M	-1.26M	-10.87M
Balance Sheet
Total Assets	12.41M	6.72M	8.97M	3.24M	3.15M	3.92M
Cash, Cash Equivalents and Short-Term Investments	8.62M	3.67M	7.62M	645.00K	584.00K	527.00K
Total Debt	3.20M	268.00K	3.44M	18.12M	13.20M	6.30M
Total Liabilities	10.82M	6.22M	41.26M	20.56M	15.03M	9.32M
Stockholders Equity	1.76M	641.00K	-32.29M	-17.21M	-11.83M	-5.12M
Cash Flow
Free Cash Flow	-16.53M	-17.16M	-2.98M	-2.09M	-2.36M	-7.84M
Operating Cash Flow	-16.51M	-17.14M	-2.48M	-2.08M	-2.25M	-7.82M
Investing Cash Flow	-64.00K	-22.00K	-504.00K	980.94K	823.32K	-20.00K
Financing Cash Flow	21.96M	13.21M	10.07M	1.31M	1.08M	5.96M

Serina Therapeutics Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 2.69
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SER, the sentiment is Neutral. The current price of 2.69 is above the 20-day moving average (MA) of 2.45, below the 50-day MA of 3.21, and below the 200-day MA of 4.88, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 49.08 is Neutral, neither overbought nor oversold. The STOCH value of 65.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SER.

Serina Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SKYE	48 Neutral	$32.70M	-0.75	-94.31%	―	―	-53.18%
CELU	44 Neutral	$38.35M	-0.39	―	―	-15.81%	-113.06%
BRNS	44 Neutral	$30.82M	-0.39	-62.30%	―	-100.00%	-26.30%
SER	42 Neutral	$28.47M	-0.45	―	―	―	―
OTLK	42 Neutral	$34.62M	-0.48	―	―	―	86.28%

Serina Therapeutics Corporate Events

Serina Therapeutics Faces NYSE American Compliance Deficiency Notice

On January 9, 2026, Serina Therapeutics received a deficiency notification from NYSE American stating the company is not in compliance with the exchange’s minimum stockholders’ equity requirements, after reporting equity of $1.6 million as of September 30, 2025 and losses in three of its four most recent fiscal years ended December 31, 2024. Serina has until February 8, 2026 to submit a remediation plan outlining actions to regain compliance by July 9, 2027, during which its shares will continue trading on NYSE American with enhanced oversight; acceptance of the plan would allow the company to remain listed through the cure period, while rejection would trigger delisting proceedings, creating added uncertainty for shareholders even as the company’s day-to-day operations and SEC reporting obligations remain unaffected in the near term.

The most recent analyst rating on (SER) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.

Serina Therapeutics Holds 2025 Annual Stockholders Meeting

On November 7, 2025, Serina Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders. During the meeting, Steve Ledger and Karen J. Wilson were elected as directors to serve until the 2028 Annual Meeting. Additionally, the appointment of Frazier & Deeter, LLC as the company’s independent auditors for the 2025 fiscal year was ratified. The issuance of common stock related to the Convertible Note and Warrants was also approved.

The most recent analyst rating on (SER) stock is a Sell with a $4.00 price target. To see the full list of analyst forecasts on Serina Therapeutics stock, see the SER Stock Forecast page.